Transfer factor therapy in patients with cancer

R. M. Vetto, D. R. Burger, J. E. Nolte, Arthur Vandenbark, H. W. Baker

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The objective of this study was to utilize transfer factor to stimulate cell mediated immunity to specific tumor antigens in cancer patients. Thirty five selected patients with advanced recurrent cancer, who were not suitable for further conventional therapy, were treated with transfer factor. Transfer factor was prepared from cohabitants of the patients and administered at 2 week intervals. This immunotherapeutic approach produced a clinical effect in 13 patients in terms of regression of tumor (1), arrest of metastatic disease (14), or pain relief (14). Conversion of dermal reactivity to specific tumor antigens was observed during periods of clinical improvement. Despite continued immunotherapy, the duration of clinical improvement was short (2 weeks to 12 months). Seven of the 11 patients not responding to therapy exhibited serum blocking of lymphocyte responsiveness. In 11 patients there is insufficient data to evaluate the clinical effectiveness of this therapy. The results suggest that transfer factor can stimulate specific cell mediated immunity in cancer patients and produce a clinical effect on tumor under certain circumstances.

Original languageEnglish (US)
Pages (from-to)90-97
Number of pages8
JournalCancer
Volume37
Issue number1
DOIs
StatePublished - 1976

Fingerprint

Transfer Factor
Neoplasms
Neoplasm Antigens
Cellular Immunity
Therapeutics
Immunotherapy
Lymphocytes
Pain
Skin
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Transfer factor therapy in patients with cancer. / Vetto, R. M.; Burger, D. R.; Nolte, J. E.; Vandenbark, Arthur; Baker, H. W.

In: Cancer, Vol. 37, No. 1, 1976, p. 90-97.

Research output: Contribution to journalArticle

Vetto, R. M. ; Burger, D. R. ; Nolte, J. E. ; Vandenbark, Arthur ; Baker, H. W. / Transfer factor therapy in patients with cancer. In: Cancer. 1976 ; Vol. 37, No. 1. pp. 90-97.
@article{4faa20d92d9f466ea9d6b278b3efe351,
title = "Transfer factor therapy in patients with cancer",
abstract = "The objective of this study was to utilize transfer factor to stimulate cell mediated immunity to specific tumor antigens in cancer patients. Thirty five selected patients with advanced recurrent cancer, who were not suitable for further conventional therapy, were treated with transfer factor. Transfer factor was prepared from cohabitants of the patients and administered at 2 week intervals. This immunotherapeutic approach produced a clinical effect in 13 patients in terms of regression of tumor (1), arrest of metastatic disease (14), or pain relief (14). Conversion of dermal reactivity to specific tumor antigens was observed during periods of clinical improvement. Despite continued immunotherapy, the duration of clinical improvement was short (2 weeks to 12 months). Seven of the 11 patients not responding to therapy exhibited serum blocking of lymphocyte responsiveness. In 11 patients there is insufficient data to evaluate the clinical effectiveness of this therapy. The results suggest that transfer factor can stimulate specific cell mediated immunity in cancer patients and produce a clinical effect on tumor under certain circumstances.",
author = "Vetto, {R. M.} and Burger, {D. R.} and Nolte, {J. E.} and Arthur Vandenbark and Baker, {H. W.}",
year = "1976",
doi = "10.1002/1097-0142(197601)37:1<90::AID-CNCR2820370113>3.0.CO;2-U",
language = "English (US)",
volume = "37",
pages = "90--97",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Transfer factor therapy in patients with cancer

AU - Vetto, R. M.

AU - Burger, D. R.

AU - Nolte, J. E.

AU - Vandenbark, Arthur

AU - Baker, H. W.

PY - 1976

Y1 - 1976

N2 - The objective of this study was to utilize transfer factor to stimulate cell mediated immunity to specific tumor antigens in cancer patients. Thirty five selected patients with advanced recurrent cancer, who were not suitable for further conventional therapy, were treated with transfer factor. Transfer factor was prepared from cohabitants of the patients and administered at 2 week intervals. This immunotherapeutic approach produced a clinical effect in 13 patients in terms of regression of tumor (1), arrest of metastatic disease (14), or pain relief (14). Conversion of dermal reactivity to specific tumor antigens was observed during periods of clinical improvement. Despite continued immunotherapy, the duration of clinical improvement was short (2 weeks to 12 months). Seven of the 11 patients not responding to therapy exhibited serum blocking of lymphocyte responsiveness. In 11 patients there is insufficient data to evaluate the clinical effectiveness of this therapy. The results suggest that transfer factor can stimulate specific cell mediated immunity in cancer patients and produce a clinical effect on tumor under certain circumstances.

AB - The objective of this study was to utilize transfer factor to stimulate cell mediated immunity to specific tumor antigens in cancer patients. Thirty five selected patients with advanced recurrent cancer, who were not suitable for further conventional therapy, were treated with transfer factor. Transfer factor was prepared from cohabitants of the patients and administered at 2 week intervals. This immunotherapeutic approach produced a clinical effect in 13 patients in terms of regression of tumor (1), arrest of metastatic disease (14), or pain relief (14). Conversion of dermal reactivity to specific tumor antigens was observed during periods of clinical improvement. Despite continued immunotherapy, the duration of clinical improvement was short (2 weeks to 12 months). Seven of the 11 patients not responding to therapy exhibited serum blocking of lymphocyte responsiveness. In 11 patients there is insufficient data to evaluate the clinical effectiveness of this therapy. The results suggest that transfer factor can stimulate specific cell mediated immunity in cancer patients and produce a clinical effect on tumor under certain circumstances.

UR - http://www.scopus.com/inward/record.url?scp=0017264805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017264805&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(197601)37:1<90::AID-CNCR2820370113>3.0.CO;2-U

DO - 10.1002/1097-0142(197601)37:1<90::AID-CNCR2820370113>3.0.CO;2-U

M3 - Article

C2 - 1247971

AN - SCOPUS:0017264805

VL - 37

SP - 90

EP - 97

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -